D. E. Shaw & Co., Inc. Oramed Pharmaceuticals Inc. Transaction History
D. E. Shaw & Co., Inc.
- $98.6 Billion
- Q2 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Oramed Pharmaceuticals Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 38,566 shares of ORMP stock, worth $92,558. This represents 0.0% of its overall portfolio holdings.
Number of Shares
38,566
Previous 70,502
45.3%
Holding current value
$92,558
Previous $205,000
51.71%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ORMP
# of Institutions
65Shares Held
6.37MCall Options Held
0Put Options Held
0-
Murchinson Ltd. Toronto, A61.7MShares$4.08 Million0.77% of portfolio
-
Bml Capital Management, LLC Zionsville, IN1.35MShares$3.24 Million2.47% of portfolio
-
Boothbay Fund Management, LLC New York, NY825KShares$1.98 Million0.06% of portfolio
-
Morgan Jess S & CO Inc366KShares$879,3622.07% of portfolio
-
Rathbones Group PLC Liverpool, X0290KShares$695,5270.0% of portfolio
About ORAMED PHARMACEUTICALS INC.
- Ticker ORMP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 38,827,100
- Market Cap $93.2M
- Description
- Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for th...